Watching
VEEV · Veeva Systems Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 22 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $281.93, the 1 October 2026 close that preceded the advance to a new 52-week high. Fiscal third-quarter revenue under the $932 million guidance floor, or a cut to the $3,682–3,687 million annual outlook, would also break the case.
Open pick Medium conviction, opened at $322.55. Kill line at open: $281.93 (daily close); graded by at the latest.
How picks are graded →The thesis
Veeva Systems is a life-sciences software vendor whose Vault customer relationship management (CRM) product is winning large drugmakers from Salesforce, and the fiscal third-quarter report, est. 2 December 2026, decides whether revenue meets the $932–935 million guidance issued on 26 August 2026. A daily close below $281.93 would break the recovery case.
The shares closed at $313.03 on 15 October 2026, a 52-week high, and 58.6% above their level three months earlier. The previous note recorded a close of $281.93 on 1 October 2026 and a 52-week high of $306.22. The shares have since cleared that high.
The narrative is maturing: mainstream coverage is in, including a 2 October 2026 segment in which Jim Cramer said software stocks including Salesforce, Veeva and Palantir led a third-quarter comeback, yet the shares set a new high on 15 October 2026. The newest operating item is the 13 October 2026 IQVIA announcement. The reported financials have not changed since 26 August 2026: revenue of $928.0 million, subscription revenue growth of 16% and 12 top-20 biopharma commitments to Vault CRM.
Bullish and bearish views on Veeva Systems Inc.
The bull case on Veeva Systems Inc. (VEEV), in brief: Subscription growth anchors the recovery. The bear case: Many published targets are below the close.
Bull case
- Subscription growth anchors the recovery. Veeva's 26 August 2026 results reported fiscal second-quarter subscription revenue of $766.8 million, up 16% year over year, and total revenue of $928.0 million, up 18%. Subscription growth below 16% at the next report would weaken this point.
- IQVIA widened its Veeva commitment. On 13 October 2026 IQVIA said it is adopting Veeva's CTMS (clinical trial management), eTMF (electronic trial master file), Study Startup and Site Connect applications as enterprise standards across its clinical development studies. This extends the electronic data capture partnership announced in August 2025, and sponsors can obtain Veeva clinical applications through IQVIA.
- Large customers committed to Vault CRM. Veeva's 26 August 2026 prepared remarks cited more than 180 live Vault CRM customers and 12 top-20 biopharma commitments after two additional August commitments.
- Annual outlook was raised. On 26 August 2026 Veeva raised fiscal 2027 revenue guidance to $3,682–3,687 million. Fiscal 2027 runs February 2026 to January 2027.
- AI products broaden the story. On 24 September 2026 Veeva announced a Study Builder Agent that configures clinical-trial software from a study protocol, delivered as a Claude Cowork plugin, with early-adopter availability planned for December 2026 and no additional license, per Veeva's release.
- Some targets sit above the close. Wells Fargo's Stan Berenshteyn raised his target to $330 on 9 September 2026, per TipRanks. RBC's target is $325, set on 27 August 2026. Barclays' target is $315, also set on 27 August 2026.
Bear case
- Many published targets are below the close. Of the 27 August 2026 and 28 August 2026 target changes, Canaccord Genuity's $260, BMO Capital's $270, Citigroup's $273, Mizuho's $280, TD Cowen's $283, UBS's $290 and Baird's $300 are all under the $313.03 close on 15 October 2026. Some of these firms may have updated since.
- Consensus targets trail the price. Stockanalysis.com showed a consensus target of $297.3 in the previous note, and Benzinga showed $290 on 4 September 2026. Both sit below the latest close.
- Salesforce competition persists. Salesforce's 15 September 2026 Life Sciences keynote agenda listed executives from Takeda, AstraZeneca and Fresenius Kabi. A named drugmaker replacing Veeva CRM with Salesforce would be direct evidence of displacement.
- Subscription growth trails total growth. Subscription revenue grew 16% on 26 August 2026 while total revenue grew 18%, with professional services revenue at $161.2 million. A further subscription slowdown at the next report would show that migration work inflated the total.
- Reported margin sits well below adjusted margin. The 26 August 2026 release showed a 44.8% operating margin under management's non-GAAP measure and 29.6% under generally accepted accounting principles (GAAP).
- New AI products have no revenue yet. The Study Builder Agent is not available until December 2026, so the 24 September 2026 announcement adds no reported revenue.
Price setup
Adjusted daily closes show $313.03 on 15 October 2026, equal to the 52-week high, with a 14-day relative strength index (RSI) of 72.5. Readings above 70 are conventionally read as stretched after a rapid advance. The 3-month gain of 58.6% reflects the move that began after the 26 August 2026 report.
The close of $281.93 on 1 October 2026 is the level whose loss would return the shares to the range they held before the latest advance. Crowding evidence is the new high at an elevated RSI, mainstream commentary such as the 2 October 2026 Cramer segment, and a majority of the dated analyst targets below the price.
Catalysts, next 30 days
- ~2 December 2026, est.: Fiscal third-quarter 2027 results, outside the 30-day window but the event that tests the $932–935 million guidance.
- 2026-12, planned: Study Builder Agent early-adopter availability.
Elapsed catalysts
- 20 October to 21 October 2026: Veeva R&D and Quality Summit in Boston, with IQVIA presenting a clinical data session on 20 October 2026. Product and customer disclosures can extend the IQVIA and Vault CRM evidence. (passed 2d ago)
What would change the view
The case breaks if fiscal third-quarter revenue lands below the $932 million guidance floor, if the $3,682–3,687 million annual outlook is cut, or if subscription growth falls below the 16% reported on 26 August 2026. A named drugmaker moving from Veeva CRM to Salesforce would also weaken the Vault CRM evidence. On price, a daily close below $281.93 would erase the advance made since 1 October 2026.
The case strengthens if the 20 October 2026 summit adds named top-20 biopharma commitments to Vault CRM beyond the 12 reported on 26 August 2026, or if analysts raise targets to or above the market price.
What it trades with
Veeva trades with large-cap enterprise software. The 2 October 2026 Cramer segment grouped it with Salesforce and Palantir as leaders of the third-quarter software recovery, and Salesforce is also its main CRM competitor. IQVIA is both a customer and partner after the August 2025 resolution of disputes. A drop in software shares tied to AI worries could move Veeva regardless of its own results.
Notes
- Fiscal year ends 31 January: fiscal 2027 spans February 2026 to January 2027, so fiscal and calendar labels differ by nearly a year.
- Veeva is a Delaware public benefit corporation, so the board must balance stakeholder interests alongside shareholder return.
- Operating income guidance is non-GAAP; GAAP operating margin was 29.6% in fiscal Q2 2027 versus 44.8% non-GAAP.
Related · shared themes
ACN
Accenture PLC
Accenture's 14 October 2026 Investor Day plan for mid-single-digit growth still supports its recovery case, but Baird's 21 October 2026 downgrade marks a full valuation; the December first-quarter report shows whether record bookings become revenue.
AMPL
Amplitude, Inc.
Amplitude's 21% revenue growth and raised outlook have doubled its shares in three months, to a $16.52 high on 21 October 2026; the 4 November 2026 third-quarter report tests revenue against $105.6–108.0 million and net retention against 103%.
GTLB
GitLab Inc.
GitLab's usage-based Flex pricing for AI coding agents has to lift fiscal Q3 revenue above its $281–$283 million guidance; the fiscal Q3 report, expected about 1 December 2026, settles it. The shares closed at $55.45 on 21 October 2026, 1.0% below their 52-week high.
INTU
Intuit Inc.
Intuit is answering the AI-agent threat and its price problem with products and deals: free-federal Credit Karma Tax, the Sequence purchase and a QuickBooks connector in Meta's Muse. The fiscal first-quarter report expected around 19 November 2026 shows whether customer growth restarts.
See also · stocks to watch